Home > Newsletters > Drug Industry Daily > Seroquel XR Formulation Patent Deemed Valid, Good Through 2017
Drug Industry Daily
April 2, 2012 | Vol. 11 No. 65
Seroquel XR Formulation Patent Deemed Valid, Good Through 2017
With the initial version of AstraZeneca’s antipsychotic Seroquel now victim to a host of generic rivals, the drugmaker can be confident the product’s extended-release version is likely safe for another five years.
Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapCourt Stays Seven Wyeth, Teva Pay-for-Delay Cases Pending Supreme Court Petitions PhRMA Asks Supreme Court to Reverse Third Circuit’s ‘Rogue’ Anti-Pay-for-Delay DecisionDistrict Court Stays Four Cephalon Pay-for-Delay Cases Pending Merck’s Supreme Court Petition
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.